AgomAb Therapeutics (NASDAQ:AGMB) Trading 5.1% Higher – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB) was up 5.1% on Tuesday . The company traded as high as $13.60 and last traded at $13.84. Approximately 154,661 shares were traded during trading, an increase of 18% from the average session volume of 131,241 shares. The stock had previously closed at $13.17.

Wall Street Analyst Weigh In

A number of equities analysts have commented on AGMB shares. Piper Sandler started coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price for the company. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. B. Riley Financial assumed coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Finally, HC Wainwright started coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Trading Up 3.1%

The company has a fifty day simple moving average of $13.23.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Analysts predict that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.